TY - JOUR T1 - Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience’ by Pineda-Sic <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e86 LP - e86 DO - 10.1136/annrheumdis-2020-218223 VL - 80 IS - 6 AU - Hendrik Schulze-Koops AU - Klaus Krueger AU - Christof Specker A2 - , Y1 - 2021/06/01 UR - http://ard.bmj.com/content/80/6/e86.abstract N2 - With great interest but also some concerns we read the study of Dr Pineda-Sic et al 1 on treatment adherence of patients with inflammatory rheumatic diseases (IRD) during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 pandemic in Latin America. In an anonymous electronic survey of consecutive patients at the rheumatology outpatient clinic of the university hospital in Monterrey, Mexico, the authors requested information about treatment adherence from patients with IRD. From the 345 patients who responded between 14 and 25 May 2020, 293 (85%) had not changed their medication. Importantly, 91.3% of all patients indicated that they knew about the benefits of their treatment.These data are reassuring, as current guidelines, for example by the German Society of Rheumatology (DGRh eV),2 the European League Against Rheumatism3 or the American College of Rheumatology, … ER -